RXi Pharmaceuticals Corp Share Price Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 7.5Cr 624.4Cr | Capitalization | 36.13L 30Cr |
---|---|---|---|---|---|
Net income 2024 * | -90L -75Cr | Net income 2025 * | 4.7Cr 391.29Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
0.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/17/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Director/Board Member | 73 | 02/22/02 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/13/18 |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 5.09TCr | |
-0.56% | 4.21TCr | |
+49.62% | 4.2TCr | |
-7.20% | 2.92TCr | |
+12.59% | 2.6TCr | |
-21.51% | 1.89TCr | |
+6.92% | 1.32TCr | |
+24.91% | 1.22TCr | |
+29.60% | 1.22TCr |